Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting

Merck & Co Inc MRK has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless of PD-L1 expression.

  • Adjuvant treatment with Keytruda resulted in a statistically significant and clinically meaningful improvement in disease-free survival (DFS) compared with placebo in stage IB-IIIA non-small cell lung cancer (NSCLC).
  • At the interim analysis, there was also an improvement in DFS for patients whose tumors express PD-L1 (tumor proportion score [TPS] ≥50%) treated with Keytruda compared to placebo; however, this dual primary endpoint did not meet statistical significance.
  • The trial will continue to analyze DFS in patients whose tumors express high levels of PD-L1 (TPS ≥50%) and evaluate overall survival (OS), a key secondary endpoint.
  • Price Action: MRK shares are up 0.24% at $80.49 during the premarket session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsNon-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!